<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of medication adjustments for adult patients with cirrhosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of medication adjustments for adult patients with cirrhosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of medication adjustments for adult patients with cirrhosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph Jennings, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James H Lewis, MD, FACP, FACG, AGAF, FAASLD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bruce A Runyon, MD, FAASLD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 15, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1665586835"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The liver is responsible for the selective uptake, concentration, metabolism, and excretion of most drugs. Both prescription and over-the-counter medications can cause hepatotoxicity through a variety of mechanisms. Measures such as drug dose adjustment can help prevent adverse drug reactions (eg, acute kidney injury) in patients with cirrhosis. </p><p>This topic will discuss the impact of cirrhosis on pharmacokinetics and medication adjustments for patients with cirrhosis. </p><p>The hepatic metabolism of drugs and the mechanisms by which drugs might injure a normal liver are discussed separately. (See  <a class="medical medical_review" href="/d/html/3568.html" rel="external">"Drugs and the liver: Metabolism and mechanisms of injury"</a>.)</p><p>The clinical patterns of drug-induced hepatotoxicity are discussed separately. (See  <a class="medical medical_review" href="/d/html/3571.html" rel="external">"Drug-induced liver injury"</a>.)</p><p>An overview of complications and general management of patients with cirrhosis is discussed separately. (See  <a class="medical medical_review" href="/d/html/1263.html" rel="external">"Cirrhosis in adults: Overview of complications, general management, and prognosis"</a>.)</p><p class="headingAnchor" id="H3937692219"><span class="h1">IMPACT OF CIRRHOSIS ON PHARMACOKINETICS</span><span class="headingEndMark"> — </span>Cirrhosis may result in hemodynamic changes and complications (eg, ascites) that may impact drug pharmacokinetics; however, the effect of these factors is variable depending on patient characteristics (eg, severity of cirrhosis) and the specific drug [<a href="#rid1">1,2</a>].</p><p>Risk factors for adverse drug reactions in patients with cirrhosis include [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Alterations in hepatic blood flow – Alterations in hepatic blood flow resulting in lower first-pass drug extraction may be due to decreased portal blood flow, increased hepatic arterial resistance, and/or portosystemic shunting [<a href="#rid2">2,4</a>]. In addition, patients with cirrhosis may develop capillarization of the hepatic sinusoids, and this impedes the transfer of substrates to the hepatocytes for metabolism [<a href="#rid5">5</a>]. This may lead to increased bioavailability and higher serum concentrations of some drugs. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Portosystemic shunting – In addition to decreasing first-pass drug metabolism, portosystemic shunts may permit cardioactive substances to bypass the liver, resulting in altered electrophysiology of the heart (eg, prolongation of the QTc interval) [<a href="#rid6">6,7</a>]. (See  <a class="medical medical_review" href="/d/html/1043.html" rel="external">"Acquired long QT syndrome: Definitions, pathophysiology, and causes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Changes in cytochrome P450 activity – Cytochrome P450 metabolic activity is altered in patients with cirrhosis, and the effect depends on the severity of liver disease and the specific cytochrome P450 enzyme [<a href="#rid8">8,9</a>]. The loss of function from some cytochrome P450 enzymes results in lower first-pass drug extraction, and this leads to increased serum drug levels of selected medications (eg, <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a>) [<a href="#rid3">3,9-11</a>]. The mechanisms of hepatic metabolism of exogenous products are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/3568.html" rel="external">"Drugs and the liver: Metabolism and mechanisms of injury", section on 'Role of the liver in drug metabolism'</a> and  <a class="medical medical_review" href="/d/html/2904.html" rel="external">"Overview of pharmacogenomics", section on 'CYP isoenzymes and drug metabolism'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypoalbuminemia – Patients with cirrhosis may have decreased albumin as the result of a combination of impaired production and dilution from fluid retention [<a href="#rid12">12</a>]. Drugs with a high-binding profile to albumin can therefore have more unbound drug in the serum, which may impact the clearance of and toxicity risk from these medications [<a href="#rid3">3,13</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cholestasis – Impaired bilirubin secretion and bile formation can impact drug clearance and subsequently increase serum drug levels, resulting in toxicity [<a href="#rid3">3,11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Portal hypertension – Portal hypertension indirectly affects drug metabolism by the following mechanisms (see  <a class="medical medical_review" href="/d/html/90896.html" rel="external">"Portal hypertension in adults"</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ascites – Ascites can impact the volume of distribution for some drugs [<a href="#rid3">3,11,14</a>]. Ascites can also contribute to intestinal edema and impaired permeability, which impacts bioavailability of oral medications [<a href="#rid3">3,11</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Portal gastropathy – Portal gastropathy can impact absorption of oral medications and impact the drug's bioavailability [<a href="#rid3">3,11</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Renal blood flow – Hemodynamic changes related to portal hypertension can impact renal blood flow, leading to decreased renal clearance of medications, particularly for patients with decompensated cirrhosis [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/d/html/2308.html" rel="external">"Hepatorenal syndrome"</a> and <a class="local">'Factors that guide decision-making'</a> below.)</p><p></p><p class="headingAnchor" id="H2857380962"><span class="h1">GENERAL PRINCIPLES</span></p><p class="headingAnchor" id="H4075298198"><span class="h2">Factors that guide decision-making</span><span class="headingEndMark"> — </span>Drug selection and dose adjustments are guided by the following factors:</p><p class="bulletIndent1"><span class="glyph">●</span>Indication for drug therapy (ie, underlying diagnosis, need for long-term therapy)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pharmacokinetics of the medication (eg, hepatic metabolism, excretion) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Safety of alternative medications</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Coexisting conditions (eg, renal impairment)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Concurrent medications (ie, risk of drug-drug interaction) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severity of liver disease, which may be categorized using a clinical definition (ie, compensated or decompensated cirrhosis) or a predictive model (ie, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.mayoclinic.org%2Fmedical-professionals%2Ftransplant-medicine%2Fcalculators%2Fprobability-of-mortality-following-transjugular-intrahepatic-portosystemic-shunts%2Fitt-20434720&amp;token=%2BOzjRemjaJl%2Br2KOdvp3YCjcnImvzHYP1x2uctOGWF60fJ1IwCwZQFA8htWQaxYFrCHeX59pNV0uS0pEQYOvF219kmR8jfH2LHaAGSszln357l77YK6fDRbbnzijSTcDzlPKNiqVcM9De681N31mHFVnWA6SgNND5vP6A7v9XWKuH7g4cJuHyenaPn%2BAHs%2BB&amp;TOPIC_ID=121754" target="_blank">Model for End-stage Liver Disease</a> score or Child-Pugh classification). For example, patients who have not developed a major complication are classified as having compensated cirrhosis, whereas patients who have a complication (eg, variceal bleeding, new onset ascites, spontaneous bacterial peritonitis, hepatic encephalopathy) are classified as having decompensated cirrhosis. Prognostic classifications are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/1263.html" rel="external">"Cirrhosis in adults: Overview of complications, general management, and prognosis", section on 'Prognosis'</a>.)</p><p></p><p>In general, drug and herbal medication use should be minimized in patients with cirrhosis. For example, some patients are taking medications without a clear indication (eg, proton pump inhibitors). In addition, some drugs are initiated during an inpatient hospitalization and continued after hospital discharge but without an indication for long-term use [<a href="#rid15">15</a>].<strong> </strong></p><p class="headingAnchor" id="H829478955"><span class="h2">Rationale for dose modification</span><span class="headingEndMark"> — </span>Data on drug dose modification for patients with cirrhosis are limited, although empiric dose reduction combined with clinical monitoring (eg, liver biochemical and function tests) is a commonly used strategy to reduce the risk of adverse drug reactions (ADRs) [<a href="#rid11">11,14</a>]. (See  <a class="medical medical_review" href="/d/html/3576.html" rel="external">"Approach to the patient with abnormal liver biochemical and function tests", section on 'Common liver biochemical and function tests'</a>.) Historically, dosing adjustments were largely based on expert opinion. </p><p>Suggestions to guide dose adjustment include grouping drugs based on the degree of hepatic extraction (ie, first-pass metabolism) and grouping patients based on severity of cirrhosis [<a href="#rid3">3,11,14</a>]. For example, drugs with higher rates of hepatic extraction would be expected to have higher serum drug levels as liver disease progresses, thus requiring dose reduction [<a href="#rid3">3,11</a>]. Conversely, a drug that does not undergo first-pass metabolism may not need initial dose adjustment on the basis of hepatic impairment.</p><p>Predictive models for drug metabolism based on severity of liver disease show promise [<a href="#rid4">4,16</a>]. One such model predicted an increase in the serum concentrations of 45 medications in patients with either Child-Pugh classes A or B disease [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/d/html/1263.html" rel="external">"Cirrhosis in adults: Overview of complications, general management, and prognosis", section on 'Prognosis'</a>.)</p><p class="headingAnchor" id="H3801858149"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>When a patient with cirrhosis begins a medication, we monitor the patient for signs of decompensation (eg, ascites, hepatic encephalopathy) or extrahepatic ADRs (eg, rash), in addition to advising the patient to report any side effects (eg, anorexia, nausea) [<a href="#rid18">18</a>]. The monitoring plan is individualized based on the risk of drug toxicity, the severity of cirrhosis, and the patient's coexisting conditions. </p><p>Many medications can be used safely in patients with cirrhosis, provided that clinicians are observing for ADRs, drug-drug interactions, and the need for dose adjustment if liver disease progresses or comorbid conditions (eg, renal impairment) develop [<a href="#rid3">3,11,19</a>].</p><p class="headingAnchor" id="H677236058"><span class="h2">Multidisciplinary team</span><span class="headingEndMark"> — </span>Medication selection, dose adjustments, and monitoring for patients with cirrhosis typically involve a multidisciplinary approach (hepatology, primary care, pharmacy, and other medical subspecialties [eg, nephrology]). </p><p class="headingAnchor" id="H831950418"><span class="h1">DRUGS FOR CIRRHOSIS-RELATED CONDITIONS</span><span class="headingEndMark"> — </span>For specific drug prescribing information, please refer to the Lexicomp database and drug label information.</p><p class="headingAnchor" id="H766978248"><span class="h2">Portal hypertension and varices</span><span class="headingEndMark"> — </span>Nonselective beta blockers are used for treating portal hypertension complicated by varices to reduce the risk of variceal hemorrhage. Most beta blockers (except <a class="drug drug_general" data-topicid="9672" href="/d/drug information/9672.html" rel="external">nadolol</a>) primarily undergo first-pass metabolism; therefore, increased plasma concentrations can be expected. Therefore, dosing strategy typically includes initiating a low dose and titrating the dose based on blood pressure (ie, maintaining mean arterial pressure &gt;82 mmHg (<a class="calc calc_professional" href="/d/html/101851.html" rel="external">calculator 1</a>)) and based on heart rate response while observing for adverse effects (eg, fatigue, acute kidney injury) [<a href="#rid3">3,20</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>For primary prevention of esophageal variceal hemorrhage, the dosing and safety of beta blockers are discussed separately. (See  <a class="medical medical_review" href="/d/html/1245.html" rel="external">"Primary prevention of bleeding from esophageal varices in patients with cirrhosis", section on 'Preventive strategies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For prevention of recurrent variceal bleeding in patients with esophageal varices, the dosing and safety of beta blockers are discussed separately. (See  <a class="medical medical_review" href="/d/html/1252.html" rel="external">"Prevention of recurrent bleeding from esophageal varices in patients with cirrhosis"</a>.)</p><p></p><p>However, we avoid the following beta blockers for patients with cirrhosis:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9540" href="/d/drug information/9540.html" rel="external">Labetalol</a>: Labetalol, a beta and alpha blocker, has been associated with fatal drug-induced liver injury [<a href="#rid21">21</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9461" href="/d/drug information/9461.html" rel="external">Nebivolol</a>: Nebivolol, a beta 1 selective blocker, has been shown to increase portal pressures [<a href="#rid22">22,23</a>]. </p><p></p><p>Adverse effects of beta blockers, including issues related to patients with ascites or hyponatremia, are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/967.html" rel="external">"Major side effects of beta blockers"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2326.html" rel="external">"Hyponatremia in patients with cirrhosis", section on 'Discontinue beta blockers and other antihypertensive drugs'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1258.html" rel="external">"Ascites in adults with cirrhosis: Diuretic-resistant ascites", section on 'Discontinuing beta blockers'</a>.)</p><p></p><p class="headingAnchor" id="H1411885131"><span class="h2">Ascites</span><span class="headingEndMark"> — </span>Ascites is the most common complication of cirrhosis, and splanchnic arterial vasodilation contributes to ascites formation. The pathogenesis of ascites is discussed separately. (See  <a class="medical medical_review" href="/d/html/1259.html" rel="external">"Pathogenesis of ascites in patients with cirrhosis"</a>.)</p><p>Diuretic therapy for ascites typically consists of <a class="drug drug_general" data-topicid="9943" href="/d/drug information/9943.html" rel="external">spironolactone</a> and <a class="drug drug_general" data-topicid="8482" href="/d/drug information/8482.html" rel="external">furosemide</a> (see  <a class="medical medical_review" href="/d/html/1256.html" rel="external">"Ascites in adults with cirrhosis: Initial therapy", section on 'Diuretic therapy'</a>): </p><p class="bulletIndent1"><span class="glyph">●</span>Potassium sparing diuretics – <a class="drug drug_general" data-topicid="9943" href="/d/drug information/9943.html" rel="external">Spironolactone</a>, a potassium sparing diuretic, is safe for use in patients with cirrhosis, and other drugs in this class (eg, <a class="drug drug_general" data-topicid="8789" href="/d/drug information/8789.html" rel="external">eplerenone</a>) also appear to be safe [<a href="#rid22">22</a>]. However, additional efficacy data on eplerenone are required before this drug can be routinely used for managing ascites. In addition, we avoid <a class="drug drug_general" data-topicid="10016" href="/d/drug information/10016.html" rel="external">triamterene</a> because of the risk of extrahepatic adverse drug reactions (ADRs) (eg, megaloblastic anemia) [<a href="#rid22">22</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Loop diuretics – For patients with cirrhosis, loop diuretics (eg, <a class="drug drug_general" data-topicid="8482" href="/d/drug information/8482.html" rel="external">furosemide</a>) can be used to help potentiate diuresis and avoid hyperkalemia in the setting of <a class="drug drug_general" data-topicid="9943" href="/d/drug information/9943.html" rel="external">spironolactone</a> use [<a href="#rid24">24,25</a>]. Monitoring patients for adverse effects (eg, hyponatremia, hypo- or hyperkalemia, acute kidney injury) is discussed separately. (See  <a class="medical medical_review" href="/d/html/1256.html" rel="external">"Ascites in adults with cirrhosis: Initial therapy", section on 'Patient monitoring'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other diuretics – Vasopressin receptor antagonists are selective antagonists of vasopressin V2 receptors that cause hypotonic diuresis, which can raise serum sodium in patients with hyponatremia due to cirrhosis. However, data do not show a benefit over potassium sparing and loop diuretics for patients with ascites [<a href="#rid24">24,25</a>]. In addition, the vasopressin receptor antagonist <a class="drug drug_general" data-topicid="9512" href="/d/drug information/9512.html" rel="external">tolvaptan</a> is not approved for use in patients with cirrhosis based on US Food and Drug Administration labeling. The use of vasopressin receptor antagonists for patients with hyponatremia is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/2326.html" rel="external">"Hyponatremia in patients with cirrhosis", section on 'Vasopressin receptor antagonists'</a>.) </p><p></p><p class="headingAnchor" id="H254175465"><span class="h2">Hepatic encephalopathy</span><span class="headingEndMark"> — </span>Drug therapy for hepatic encephalopathy includes medications such as <a class="drug drug_general" data-topicid="9543" href="/d/drug information/9543.html" rel="external">lactulose</a> (a nonabsorbable disaccharide) and <a class="drug drug_general" data-topicid="10202" href="/d/drug information/10202.html" rel="external">rifaximin</a> (a nonabsorbable antibiotic) [<a href="#rid26">26</a>]. The risk of ADRs is limited to gastrointestinal side effects, and no dose adjustments are needed to reduce the risk of worsening liver disease [<a href="#rid24">24</a>]. The management of patients with hepatic encephalopathy is discussed separately. (See  <a class="medical medical_review" href="/d/html/1255.html" rel="external">"Hepatic encephalopathy in adults: Treatment"</a>.)</p><p class="headingAnchor" id="H2479101123"><span class="h1">DRUGS FOR COEXISTING CONDITIONS</span><span class="headingEndMark"> — </span>Patients with cirrhosis may have coexisting conditions (eg, diabetes mellitus) that may require drug therapy.</p><p>For specific drug-prescribing information, please refer to the Lexicomp database and drug label information.</p><p>The Health Base Foundation (The Netherlands Organization for Health Research and Development) maintains a <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.drugsinlivercirrhosis.org%2Fhealthcare-professionals%2Fdrugs%2F&amp;token=cR9HI6UFke9p3lzh%2B9ikfjyirZSa9P2c5fP%2BGMCRJtlt6%2FhI8dqdvQsm34VlewU0htDQbEW4NII0%2F2gBy5Z3e%2Fm8oJYiCCosEDPy7HwXMHw%3D&amp;TOPIC_ID=121754" target="_blank">searchable database</a> on drug safety for patients with cirrhosis [<a href="#rid22">22,27</a>].</p><p class="headingAnchor" id="H1331792024"><span class="h2">Lipid lowering agents</span><span class="headingEndMark"> — </span>We avoid <a class="drug drug_general" data-topicid="8949" href="/d/drug information/8949.html" rel="external">atorvastatin</a> for patients with cirrhosis because of higher serum drug concentrations that may increase the risk of rhabdomyolysis [<a href="#rid22">22,28,29</a>]. In addition, statins are not used for patients with decompensated cirrhosis or significant cholestasis (ie, total bilirubin &gt;1.75 mg/dL [30 microm/L]) because of increased risk of toxicity. Some patients with decompensated cirrhosis may die from liver failure before experiencing benefits from a lipid lowering agent. (See  <a class="medical medical_review" href="/d/html/3602.html" rel="external">"Hypercholesterolemia in primary biliary cholangitis (primary biliary cirrhosis)", section on 'Candidates for lipid lowering agents'</a>.)</p><p>Statins that are not extensively metabolized by the liver (eg, <a class="drug drug_general" data-topicid="9804" href="/d/drug information/9804.html" rel="external">pravastatin</a>) may be used for patients with compensated cirrhosis because the risk of liver injury is low [<a href="#rid30">30,31</a>]. Initial dosing, monitoring, and dose titration are discussed separately. (See  <a class="medical medical_review" href="/d/html/4564.html" rel="external">"Statins: Actions, side effects, and administration", section on 'Chronic liver disease'</a>.)</p><p>For patients with compensated cirrhosis, statins are associated with beneficial effects, including decreased portal pressures (<a class="drug drug_general" data-topicid="9923" href="/d/drug information/9923.html" rel="external">simvastatin</a>) and lower risk for hepatocellular carcinoma [<a href="#rid30">30,32</a>]. (See  <a class="medical medical_review" href="/d/html/3599.html" rel="external">"Epidemiology and risk factors for hepatocellular carcinoma", section on 'Statins'</a>.)</p><p class="headingAnchor" id="H910505776"><span class="h2">Antihypertensives</span><span class="headingEndMark"> — </span>Patients with cirrhosis who are treated for hypertension are closely monitored because baseline blood pressure can decline without the onset of symptoms. Antihypertensive agents are tapered or stopped for patients with low blood pressure (ie, mean arterial pressure (MAP) ≤82 mmHg). The approach to ambulatory and home blood pressure monitoring is discussed separately. (See  <a class="medical medical_review" href="/d/html/3820.html" rel="external">"Out-of-office blood pressure measurement: Ambulatory and self-measured blood pressure monitoring"</a>.) </p><p class="bulletIndent1"><span class="glyph">●</span>Angiotensin inhibition – For patients with decompensated cirrhosis and/or ascites, angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are avoided because of the risk of renal impairment, and this is discussed separately. (See  <a class="medical medical_review" href="/d/html/1256.html" rel="external">"Ascites in adults with cirrhosis: Initial therapy", section on 'Avoidance of angiotensin inhibition'</a>.)</p><p></p><p class="bulletIndent1">For patients with compensated cirrhosis and no ascites, ACEIs and ARBs are started at a low dose and dose adjustments are based on monitoring of blood pressure (ie, maintaining MAP &gt;82 mmHg), electrolytes, and kidney function, which is discussed separately. (See  <a class="medical medical_review" href="/d/html/3829.html" rel="external">"Treatment of hypertension in patients with diabetes mellitus"</a> and  <a class="medical medical_review" href="/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"</a> and  <a class="medical medical_review" href="/d/html/3852.html" rel="external">"Overview of hypertension in adults"</a>.)</p><p></p><p class="bulletIndent1">Both ACEIs and ARBs are effective for treating arterial hypertension, but they do not lower portal pressures [<a href="#rid3">3,33,34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thiazide diuretics – Available data suggest that thiazide diuretics do not increase risk of adverse drug reactions in patients with cirrhosis; however thiazide diuretics are rarely used in this setting [<a href="#rid35">35</a>]. They have minimal impact on ascites and are associated with electrolyte abnormalities (eg, hyponatremia, hypokalemia) that can precipitate hepatic encephalopathy [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/d/html/1257.html" rel="external">"Hepatic encephalopathy: Pathogenesis"</a> and  <a class="medical medical_review" href="/d/html/2326.html" rel="external">"Hyponatremia in patients with cirrhosis"</a>.)</p><p></p><p class="bulletIndent1">Adverse effects of thiazide diuretics are discussed separately. (See  <a class="medical medical_review" href="/d/html/3860.html" rel="external">"Use of thiazide diuretics in patients with primary (essential) hypertension", section on 'Side effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Calcium channel blockers (CCBs) – We avoid CCBs that do not have modifiable doses [<a href="#rid22">22</a>].<strong> </strong>For CCBs with various dosing options, we reduce the initial dose and maintain the lowest effective total daily dose. CCBs, including the dihydropyridines (eg, <a class="drug drug_general" data-topicid="9700" href="/d/drug information/9700.html" rel="external">nifedipine</a>) and nondihydropyridines (eg, <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a>), are extensively cleared by the liver, which results in high serum drug levels due to impaired liver function and extrahepatic shunting, particularly for patients with decompensated cirrhosis [<a href="#rid3">3,22</a>]. </p><p></p><p class="headingAnchor" id="H3217919219"><span class="h2">Hypoglycemic agents</span><span class="headingEndMark"> — </span>Patients with cirrhosis may also have diabetes mellitus, which is common in patients with nonalcoholic fatty liver disease [<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/d/html/3625.html" rel="external">"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults", section on 'Association with other disorders'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Insulin – Insulin is generally regarded as safe for patients with cirrhosis, while dose titration should be done cautiously because of possible coexisting conditions or symptoms (eg, early satiety, poor appetite) [<a href="#rid37">37-39</a>]. (See  <a class="medical medical_review" href="/d/html/1801.html" rel="external">"Insulin therapy in type 2 diabetes mellitus", section on 'Designing an insulin regimen'</a>.)</p><p></p><p class="bulletIndent1">The pharmacokinetics of insulin are largely unchanged in the setting of cirrhosis [<a href="#rid39">39</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">Metformin</a> – An alternative to metformin is typically used for patients with diabetes mellitus who have decompensated cirrhosis and additional risk factor(s) for lactic acidosis (eg, alcohol use, impaired renal function). The use of and contraindications to metformin for patients with diabetes mellitus are discussed separately. (See  <a class="medical medical_review" href="/d/html/1809.html" rel="external">"Metformin in the treatment of adults with type 2 diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sulfonylureas – We generally use an alternative drug rather than a sulfonylurea for patients with diabetes mellitus and cirrhosis because sulfonylureas are predominantly metabolized in the liver and are highly protein bound [<a href="#rid22">22,39</a>]. As a result, serum drug levels may be increased, and this may lead to higher risk of hypoglycemia. (See  <a class="medical medical_review" href="/d/html/1786.html" rel="external">"Sulfonylureas and meglitinides in the treatment of type 2 diabetes mellitus", section on 'Sulfonylureas'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Meglitinides – <a class="drug drug_general" data-topicid="9604" href="/d/drug information/9604.html" rel="external">Repaglinide</a> is avoided in patients with cirrhosis, because the pharmacokinetics of repaglinide are significantly altered in patients with hepatic impairment [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/d/html/1786.html" rel="external">"Sulfonylureas and meglitinides in the treatment of type 2 diabetes mellitus", section on 'Meglitinides'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10216" href="/d/drug information/10216.html" rel="external">Pioglitazone</a> – Pioglitazone is avoided in patients with decompensated cirrhosis or peripheral edema, however, it can be used for patients with compensated cirrhosis without peripheral edema [<a href="#rid22">22,37,39,40</a>]. The use of pioglitazone for treating diabetes mellitus is discussed separately. (See  <a class="medical medical_review" href="/d/html/1757.html" rel="external">"Thiazolidinediones in the treatment of type 2 diabetes mellitus", section on 'Hepatotoxicity'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sodium-glucose co-transporter 2 (SGLT2) inhibitors – SGLT2 inhibitors, such as <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a>, <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">dapagliflozin</a>, and <a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a>, promote increased urinary excretion of both sodium and glucose. These drugs appear to be safe for use in patients with cirrhosis and are being studied for treating ascites and portal hypertension [<a href="#rid41">41-43</a>]. It is important to note the risk of urinary tract infections with SGLT2 inhibitor use because infection has been associated with decompensation in patients with cirrhosis. (See  <a class="medical medical_review" href="/d/html/109245.html" rel="external">"Sodium-glucose cotransporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus"</a>.)</p><p></p><p>Contraindications to and dosing adjustments for other drugs used for treating diabetes mellitus can be found in the Lexicomp drug database and in topics on management of diabetes mellitus:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1787.html" rel="external">"Alpha-glucosidase inhibitors for treatment of diabetes mellitus"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/96015.html" rel="external">"Dipeptidyl peptidase 4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1772.html" rel="external">"Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus"</a>.)</p><p></p><p class="headingAnchor" id="H490763757"><span class="h2">Acid reducers</span></p><p class="headingAnchor" id="H2776507750"><span class="h3">Proton pump inhibitors (PPIs)</span><span class="headingEndMark"> — </span>For patients with cirrhosis and an indication for PPIs, we typically use <a class="drug drug_general" data-topicid="9104" href="/d/drug information/9104.html" rel="external">esomeprazole</a>, when available, based on pharmacokinetic data [<a href="#rid22">22,44,45</a>]. For patients with decompensated cirrhosis, <a class="drug drug_general" data-topicid="9718" href="/d/drug information/9718.html" rel="external">omeprazole</a>, <a class="drug drug_general" data-topicid="9546" href="/d/drug information/9546.html" rel="external">lansoprazole</a>, and <a class="drug drug_general" data-topicid="9519" href="/d/drug information/9519.html" rel="external">rabeprazole</a> are generally avoided [<a href="#rid22">22,24</a>]. The indications for and adverse effects of PPIs are discussed separately. (See  <a class="medical medical_review" href="/d/html/5.html" rel="external">"Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders"</a>.)</p><p>Long-term safety data for PPIs in patients with cirrhosis are uncertain because some studies suggest an increased risk of infection (eg, spontaneous bacterial peritonitis, <em>Clostridioides</em> [formerly <em>Clostridium</em>]<em> difficile</em> infection) or hepatic encephalopathy, while other studies do not [<a href="#rid24">24,46</a>].</p><p>The pharmacokinetics of PPIs vary depending on the specific drug. For example, the pharmacokinetics of <a class="drug drug_general" data-topicid="9104" href="/d/drug information/9104.html" rel="external">esomeprazole</a> are largely unchanged, while other PPIs (eg, <a class="drug drug_general" data-topicid="9718" href="/d/drug information/9718.html" rel="external">omeprazole</a>, <a class="drug drug_general" data-topicid="9546" href="/d/drug information/9546.html" rel="external">lansoprazole</a>, <a class="drug drug_general" data-topicid="9519" href="/d/drug information/9519.html" rel="external">rabeprazole</a>) have altered pharmacokinetics in the setting of hepatic impairment due to decreased rates of hepatic clearance [<a href="#rid22">22,47</a>].</p><p class="headingAnchor" id="H2365010038"><span class="h3">Histamine type 2 receptor antagonists</span><span class="headingEndMark"> — </span>We avoid <a class="drug drug_general" data-topicid="9265" href="/d/drug information/9265.html" rel="external">cimetidine</a> because it is associated with encephalopathy [<a href="#rid48">48</a>]. When histamine type 2 receptor antagonists are indicated, we use <a class="drug drug_general" data-topicid="8436" href="/d/drug information/8436.html" rel="external">famotidine</a> for patients with cirrhosis, and dose adjustments are not needed due to cirrhosis. However, dose modification is typically needed for patients with coexisting renal impairment. (See  <a class="medical medical_review" href="/d/html/2258.html" rel="external">"Medical management of gastroesophageal reflux disease in adults"</a>.)</p><p class="headingAnchor" id="H2475546657"><span class="h1">ANTIMICROBIALS TO AVOID</span><span class="headingEndMark"> — </span>We avoid the following antimicrobial agents because of the increased risk of hepatotoxicity in patients with cirrhosis [<a href="#rid3">3</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">Azithromycin</a>: We avoid azithromycin because of increased risk of acute liver injury and mortality in patients with cirrhosis [<a href="#rid49">49,50</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">Chloramphenicol</a>.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9418" href="/d/drug information/9418.html" rel="external">Erythromycin</a>.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">Ketoconazole</a>.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">Tetracycline</a>.</p><p></p><p class="headingAnchor" id="H2837024782"><span class="h1">OTHER DRUGS TO AVOID</span><span class="headingEndMark"> — </span>In addition to the high-risk drugs listed above, we avoid the following medications in patients with cirrhosis because of the increased risk of hepatotoxicity [<a href="#rid3">3,18</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9379" href="/d/drug information/9379.html" rel="external">Disulfiram</a> (see  <a class="medical medical_review" href="/d/html/108891.html" rel="external">"Alcohol use disorder: Treatment overview"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">Methotrexate</a> (see  <a class="medical medical_review" href="/d/html/7509.html" rel="external">"Major side effects of low-dose methotrexate", section on 'Hepatotoxicity'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9627" href="/d/drug information/9627.html" rel="external">Methimazole</a> (see  <a class="medical medical_review" href="/d/html/7875.html" rel="external">"Thionamides: Side effects and toxicities", section on 'Hepatotoxicity'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9684" href="/d/drug information/9684.html" rel="external">Nefazodone</a> (see  <a class="medical medical_review" href="/d/html/86265.html" rel="external">"Serotonin modulators: Pharmacology, administration, and side effects", section on 'Nefazodone'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10262" href="/d/drug information/10262.html" rel="external">Ranolazine</a> (see  <a class="medical medical_review" href="/d/html/1524.html" rel="external">"New therapies for angina pectoris", section on 'Ranolazine'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10047" href="/d/drug information/10047.html" rel="external">Vitamin A</a> (see  <a class="medical medical_review" href="/d/html/2571.html" rel="external">"Overview of vitamin A", section on 'Excess'</a>)</p><p></p><p class="headingAnchor" id="H2853063189"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H3089719664"><span class="h2">Patients with renal impairment</span><span class="headingEndMark"> — </span>Patients with cirrhosis and coexisting kidney disease may need drug dose adjustments based on the severity of renal impairment in addition to the severity of hepatic impairment (refer to Lexicomp and the drug label for dosing information for patients with renal impairment). For some patients, a multidisciplinary approach (hepatology, nephrology, pharmacy) is used to reduce the risk of adverse drug reactions.</p><p>The management of patients with hepatorenal syndrome is discussed separately. (See  <a class="medical medical_review" href="/d/html/2308.html" rel="external">"Hepatorenal syndrome"</a>.)</p><p class="headingAnchor" id="H3476547405"><span class="h2">Patients undergoing chemotherapy</span><span class="headingEndMark"> — </span>Patients with cirrhosis who are undergoing chemotherapy require monitoring with liver tests both prior to and during therapy, and chemotherapy may worsen existing liver disease. Patients with cirrhosis are screened for hepatitis B virus prior to undergoing chemotherapy, and this is discussed separately [<a href="#rid51">51</a>]. (See  <a class="medical medical_review" href="/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy"</a>.) </p><p>The relationship between liver function and chemotherapy is discussed separately. (See  <a class="medical medical_review" href="/d/html/2837.html" rel="external">"Chemotherapy hepatotoxicity and dose modification in patients with liver disease: Conventional cytotoxic agents"</a> and  <a class="medical medical_review" href="/d/html/128144.html" rel="external">"Chemotherapy hepatotoxicity and dose modification in patients with liver disease: Molecularly targeted agents"</a>.)</p><p class="headingAnchor" id="H786231174"><span class="h2">Patients undergoing anesthesia</span><span class="headingEndMark"> — </span>Patients with cirrhosis may require procedural intervention and anesthesia, and they are at increased risk for intraoperative complications and postoperative morbidity and mortality. Anesthetic management of patients with liver disease is discussed separately. (See  <a class="medical medical_review" href="/d/html/91242.html" rel="external">"Anesthesia for the patient with liver disease"</a>.)</p><p class="headingAnchor" id="H521588228"><span class="h2">Patients with hepatitis C virus infection</span><span class="headingEndMark"> — </span>Direct-acting antivirals are medications for treating patients with chronic hepatitis C virus (HCV) infection, and the pharmacology and use of these agents are discussed separately. (See  <a class="medical medical_review" href="/d/html/93242.html" rel="external">"Direct-acting antivirals for the treatment of hepatitis C virus infection"</a>.) </p><p>Certain direct-acting antiviral regimens are avoided in patients with decompensated cirrhosis and chronic HCV infection, and this is discussed separately. (See  <a class="medical medical_review" href="/d/html/16592.html" rel="external">"Management of chronic hepatitis C virus infection: Initial antiviral therapy in adults"</a> and  <a class="medical medical_review" href="/d/html/15795.html" rel="external">"Management of chronic hepatitis C virus infection: Antiviral retreatment following relapse in adults"</a>.)</p><p class="headingAnchor" id="H3909947198"><span class="h2">Patients with tuberculosis</span><span class="headingEndMark"> — </span>Hepatotoxicity syndromes associated with <a class="drug drug_general" data-topicid="8577" href="/d/drug information/8577.html" rel="external">isoniazid</a> and other antituberculous drugs are discussed separately. (See  <a class="medical medical_review" href="/d/html/477.html" rel="external">"Isoniazid hepatotoxicity"</a> and  <a class="medical medical_review" href="/d/html/488.html" rel="external">"Antituberculous drugs: An overview", section on 'Hepatotoxicity'</a>.)</p><p class="headingAnchor" id="H3418800283"><span class="h2">Patients with acute or chronic pain</span><span class="headingEndMark"> — </span>The safety of medications used for pain management in patients with cirrhosis is discussed separately. (See  <a class="medical medical_review" href="/d/html/1236.html" rel="external">"Management of pain in patients with advanced chronic liver disease or cirrhosis"</a>.)</p><p class="headingAnchor" id="H93455501"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/115541.html" rel="external">"Society guideline links: Cirrhosis"</a>.)</p><p class="headingAnchor" id="H3843953551"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with cirrhosis, risk factors for adverse drug reactions may include (see <a class="local">'Impact of cirrhosis on pharmacokinetics'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Alterations in hepatic blood flow and portosystemic shunting</p><p class="bulletIndent2"><span class="glyph">•</span>Changes in cytochrome P450 metabolic activity</p><p class="bulletIndent2"><span class="glyph">•</span>Hypoalbuminemia</p><p class="bulletIndent2"><span class="glyph">•</span>Cholestasis</p><p class="bulletIndent2"><span class="glyph">•</span>Complications of portal hypertension (ascites, portal gastropathy)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with cirrhosis, drug selection and dose adjustments are guided by the following (see <a class="local">'Factors that guide decision-making'</a> above): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Indication for therapy (ie, underlying diagnosis, need for long-term therapy)</p><p class="bulletIndent2"><span class="glyph">•</span>Drug pharmacokinetics (eg, hepatic metabolism, excretion)</p><p class="bulletIndent2"><span class="glyph">•</span>Safety of alternative medications</p><p class="bulletIndent2"><span class="glyph">•</span>Coexisting medical conditions (eg, renal impairment)</p><p class="bulletIndent2"><span class="glyph">•</span>Concurrent medications (ie, potential for drug-drug interactions)</p><p class="bulletIndent2"><span class="glyph">•</span>Severity of liver disease</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>While data on drug dose modification for patients with cirrhosis are limited, empiric dose reduction combined with clinical monitoring (eg, liver tests) is a commonly used strategy to reduce the risk of adverse drug reactions. (See <a class="local">'Rationale for dose modification'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medication selection, dose adjustments, and monitoring for patients with cirrhosis typically involve a multidisciplinary approach (hepatology, primary care, pharmacy, and other medical subspecialities). (See <a class="local">'Multidisciplinary team'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with cirrhosis may have complications that require drug therapy:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For primary or secondary prevention of esophageal variceal bleeding, the dosing and safety of beta blockers are discussed separately. (See  <a class="medical medical_review" href="/d/html/1245.html" rel="external">"Primary prevention of bleeding from esophageal varices in patients with cirrhosis"</a> and  <a class="medical medical_review" href="/d/html/1252.html" rel="external">"Prevention of recurrent bleeding from esophageal varices in patients with cirrhosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with ascites, dosing for diuretic therapy is discussed separately. (See  <a class="medical medical_review" href="/d/html/1256.html" rel="external">"Ascites in adults with cirrhosis: Initial therapy"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with hepatic encephalopathy, adverse effects of <a class="drug drug_general" data-topicid="9543" href="/d/drug information/9543.html" rel="external">lactulose</a> are mainly gastrointestinal and no dose adjustment is needed to reduce the risk of worsening liver function. (See  <a class="medical medical_review" href="/d/html/1255.html" rel="external">"Hepatic encephalopathy in adults: Treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with cirrhosis may have coexisting conditions (eg, diabetes mellitus) that require drug therapy. For specific drug-prescribing information, please refer to the Lexicomp database and drug label information. (See <a class="local">'Drugs for coexisting conditions'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Westphal JF, Brogard JM. Drug administration in chronic liver disease. Drug Saf 1997; 17:47.</a></li><li><a class="nounderline abstract_t">Franz CC, Hildbrand C, Born C, et al. Dose adjustment in patients with liver cirrhosis: impact on adverse drug reactions and hospitalizations. Eur J Clin Pharmacol 2013; 69:1565.</a></li><li><a class="nounderline abstract_t">Lewis JH, Stine JG. Review article: prescribing medications in patients with cirrhosis - a practical guide. Aliment Pharmacol Ther 2013; 37:1132.</a></li><li><a class="nounderline abstract_t">Edginton AN, Willmann S. Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis. Clin Pharmacokinet 2008; 47:743.</a></li><li><a class="nounderline abstract_t">Le Couteur DG, Fraser R, Hilmer S, et al. The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance. Clin Pharmacokinet 2005; 44:187.</a></li><li><a class="nounderline abstract_t">Trevisani F, Merli M, Savelli F, et al. QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt. J Hepatol 2003; 38:461.</a></li><li><a class="nounderline abstract_t">Bal JS, Thuluvath PJ. Prolongation of QTc interval: relationship with etiology and severity of liver disease, mortality and liver transplantation. Liver Int 2003; 23:243.</a></li><li><a class="nounderline abstract_t">Dietrich CG, Götze O, Geier A. Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance. World J Gastroenterol 2016; 22:72.</a></li><li><a class="nounderline abstract_t">Frye RF, Zgheib NK, Matzke GR, et al. Liver disease selectively modulates cytochrome P450--mediated metabolism. Clin Pharmacol Ther 2006; 80:235.</a></li><li><a class="nounderline abstract_t">Bastien MC, Leblond F, Pichette V, Villeneuve JP. Differential alteration of cytochrome P450 isoenzymes in two experimental models of cirrhosis. Can J Physiol Pharmacol 2000; 78:912.</a></li><li><a class="nounderline abstract_t">Delcò F, Tchambaz L, Schlienger R, et al. Dose adjustment in patients with liver disease. Drug Saf 2005; 28:529.</a></li><li><a class="nounderline abstract_t">Garcia-Martinez R, Caraceni P, Bernardi M, et al. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology 2013; 58:1836.</a></li><li><a class="nounderline abstract_t">Ulldemolins M, Roberts JA, Rello J, et al. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet 2011; 50:99.</a></li><li><a class="nounderline abstract_t">Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008; 64:1147.</a></li><li><a class="nounderline abstract_t">Ge PS, Runyon BA. The changing role of beta-blocker therapy in patients with cirrhosis. J Hepatol 2014; 60:643.</a></li><li><a class="nounderline abstract_t">Johnson TN, Boussery K, Rowland-Yeo K, et al. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet 2010; 49:189.</a></li><li><a class="nounderline abstract_t">Steelandt J, Jean-Bart E, Goutelle S, Tod M. A Prediction Model of Drug Exposure in Cirrhotic Patients According to Child-Pugh Classification. Clin Pharmacokinet 2015; 54:1245.</a></li><li><a class="nounderline abstract_t">Amarapurkar DN. Prescribing medications in patients with decompensated liver cirrhosis. Int J Hepatol 2011; 2011:519526.</a></li><li><a class="nounderline abstract_t">Franz CC, Egger S, Born C, et al. Potential drug-drug interactions and adverse drug reactions in patients with liver cirrhosis. Eur J Clin Pharmacol 2012; 68:179.</a></li><li><a class="nounderline abstract_t">Llach J, Ginès P, Arroyo V, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988; 94:482.</a></li><li><a class="nounderline abstract_t">Douglas DD, Yang RD, Jensen P, Thiele DL. Fatal labetalol-induced hepatic injury. Am J Med 1989; 87:235.</a></li><li><a class="nounderline abstract_t">Weersink RA, Bouma M, Burger DM, et al. Evidence-Based Recommendations to Improve the Safe Use of Drugs in Patients with Liver Cirrhosis. Drug Saf 2018; 41:603.</a></li><li><a class="nounderline abstract_t">Reiberger T, Payer BA, Schwabl P, et al. Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling. Liver Int 2013; 33:561.</a></li><li><a class="nounderline abstract_t">Kockerling D, Nathwani R, Forlano R, et al. Current and future pharmacological therapies for managing cirrhosis and its complications. World J Gastroenterol 2019; 25:888.</a></li><li><a class="nounderline abstract_t">Runyon BA, AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49:2087.</a></li><li><a class="nounderline abstract_t">Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014; 60:715.</a></li><li class="breakAll">https://www.drugsinlivercirrhosis.org/healthcare-professionals/ (Accessed on August 27, 2019).</li><li><a class="nounderline abstract_t">Wright AP, Adusumalli S, Corey KE. Statin therapy in patients with cirrhosis. Frontline Gastroenterol 2015; 6:255.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020702s057lbl.pdf (Accessed on August 27, 2019).</li><li><a class="nounderline abstract_t">Moctezuma-Velázquez C, Abraldes JG, Montano-Loza AJ. The Use of Statins in Patients With Chronic Liver Disease and Cirrhosis. Curr Treat Options Gastroenterol 2018; 16:226.</a></li><li><a class="nounderline abstract_t">Lewis JH. Clinical perspective: statins and the liver--harmful or helpful? Dig Dis Sci 2012; 57:1754.</a></li><li><a class="nounderline abstract_t">Bosch J, Gracia-Sancho J, Abraldes JG. Cirrhosis as new indication for statins. Gut 2020; 69:953.</a></li><li><a class="nounderline abstract_t">Yao H, Zhang C. Angiotensin II receptor blockers for the treatment of portal hypertension in patients with liver cirrhosis: a systematic review and meta-analysis of randomized controlled trials. Ir J Med Sci 2018; 187:925.</a></li><li><a class="nounderline abstract_t">Vlachogiannakos J, Tang AK, Patch D, Burroughs AK. Angiotensin converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease. Gut 2001; 49:303.</a></li><li><a class="nounderline abstract_t">Lucena MI, Andrade RJ, Tognoni G, et al. Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis. Eur J Clin Pharmacol 2002; 58:435.</a></li><li><a class="nounderline abstract_t">Jennings J, Faselis C, Yao MD. NAFLD-NASH: An Under-Recognized Epidemic. Curr Vasc Pharmacol 2018; 16:209.</a></li><li><a class="nounderline abstract_t">Elkrief L, Rautou PE, Sarin S, et al. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver Int 2016; 36:936.</a></li><li><a class="nounderline abstract_t">Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA, Maldonado-Garza H. Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World J Gastroenterol 2009; 15:280.</a></li><li><a class="nounderline abstract_t">Gangopadhyay KK, Singh P. Consensus Statement on Dose Modifications of Antidiabetic Agents in Patients with Hepatic Impairment. Indian J Endocrinol Metab 2017; 21:341.</a></li><li><a class="nounderline abstract_t">Armstrong MJ, Houlihan DD, Rowe IA. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 363:1185; author reply 1186.</a></li><li><a class="nounderline abstract_t">Saffo S, Taddei T. SGLT2 inhibitors and cirrhosis: A unique perspective on the comanagement of diabetes mellitus and ascites. Clin Liver Dis (Hoboken) 2018; 11:141.</a></li><li><a class="nounderline abstract_t">Saffo S, Garcia-Tsao G, Taddei T. SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension. J Diabetes 2021; 13:265.</a></li><li><a class="nounderline abstract_t">Gao Y, Wei L, Zhang DD, et al. SGLT2 Inhibitors: A New Dawn for Recurrent/Refractory Cirrhotic Ascites. J Clin Transl Hepatol 2021; 9:795.</a></li><li><a class="nounderline abstract_t">Freedberg DE, Kim LS, Yang YX. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology 2017; 152:706.</a></li><li><a class="nounderline abstract_t">Kinoshita Y, Ishimura N, Ishihara S. Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use. J Neurogastroenterol Motil 2018; 24:182.</a></li><li><a class="nounderline abstract_t">Moayyedi P, Eikelboom JW, Bosch J, et al. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology 2019; 157:682.</a></li><li><a class="nounderline abstract_t">Kumar R, Chawla YK, Garg SK, et al. Pharmacokinetics of omeprazole in patients with liver cirrhosis and extrahepatic portal venous obstruction. Methods Find Exp Clin Pharmacol 2003; 25:625.</a></li><li><a class="nounderline abstract_t">Levine ML. Cimetidine-induced coma in cirrhosis of the liver. JAMA 1978; 240:1238.</a></li><li><a class="nounderline abstract_t">Stine JG, Lewis JH. Hepatotoxicity of antibiotics: a review and update for the clinician. Clin Liver Dis 2013; 17:609.</a></li><li><a class="nounderline abstract_t">Martinez MA, Vuppalanchi R, Fontana RJ, et al. Clinical and histologic features of azithromycin-induced liver injury. Clin Gastroenterol Hepatol 2015; 13:369.</a></li><li><a class="nounderline abstract_t">Paul S, Saxena A, Terrin N, et al. Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy: A Systematic Review and Meta-analysis. Ann Intern Med 2016; 164:30.</a></li></ol></div><div id="topicVersionRevision">Topic 121754 Version 8.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9258630" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Drug administration in chronic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23588561" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Dose adjustment in patients with liver cirrhosis: impact on adverse drug reactions and hospitalizations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23638982" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Review article: prescribing medications in patients with cirrhosis - a practical guide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18840029" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15656697" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12663238" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12895263" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prolongation of QTc interval: relationship with etiology and severity of liver disease, mortality and liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26755861" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16952490" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Liver disease selectively modulates cytochrome P450--mediated metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11100940" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Differential alteration of cytochrome P450 isoenzymes in two experimental models of cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15924505" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Dose adjustment in patients with liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23423799" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21142293" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18762933" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24076364" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The changing role of beta-blocker therapy in patients with cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20170207" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26070946" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A Prediction Model of Drug Exposure in Cirrhotic Patients According to Child-Pugh Classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21994861" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Prescribing medications in patients with decompensated liver cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21842337" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Potential drug-drug interactions and adverse drug reactions in patients with liver cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3335320" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2757062" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Fatal labetalol-induced hepatic injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29330714" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Evidence-Based Recommendations to Improve the Safe Use of Drugs in Patients with Liver Cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23331709" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30833797" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Current and future pharmacological therapies for managing cirrhosis and its complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19475696" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Management of adult patients with ascites due to cirrhosis: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25042402" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25042402" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28839820" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Statin therapy in patients with cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28839820" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Statin therapy in patients with cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29572618" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The Use of Statins in Patients With Chronic Liver Disease and Cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22581301" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Clinical perspective: statins and the liver--harmful or helpful?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32139553" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Cirrhosis as new indication for statins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29470765" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Angiotensin II receptor blockers for the treatment of portal hypertension in patients with liver cirrhosis: a systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11454810" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Angiotensin converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12242604" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28676024" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : NAFLD-NASH: An Under-Recognized Epidemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26972930" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Diabetes mellitus in patients with cirrhosis: clinical implications and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19140227" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28459036" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Consensus Statement on Dose Modifications of Antidiabetic Agents in Patients with Hepatic Impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20843257" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30992805" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : SGLT2 inhibitors and cirrhosis: A unique perspective on the comanagement of diabetes mellitus and ascites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33210815" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34966642" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : SGLT2 Inhibitors: A New Dawn for Recurrent/Refractory Cirrhotic Ascites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28257716" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29605975" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31152740" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14671680" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Pharmacokinetics of omeprazole in patients with liver cirrhosis and extrahepatic portal venous obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/682299" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Cimetidine-induced coma in cirrhosis of the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24099021" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Hepatotoxicity of antibiotics: a review and update for the clinician.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25111234" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Clinical and histologic features of azithromycin-induced liver injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26595058" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy: A Systematic Review and Meta-analysis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
